Skip to content
Open access

Distinct activation mechanisms underlie ligand efficacy at a GPCR

Oct 2026 · bioRxiv · 1 citation
Biology Medicine

TL;DR

A deep mutational pharmacology approach is developed to measure how each residue in the µ-opioid receptor (µOR) shapes responses to 15 opioids, yielding ∼400,000 measurements of variant effects on signaling and expression, including full concentration-response series for three agonists.

Abstract

Ligands that bind to the same G protein-coupled receptor (GPCR) can produce widely different levels of signaling. These differences in efficacy are central to pharmacology, yet how a receptor sequence determines signaling level remains incompletely understood. Here we develop a deep mutational pharmacology approach to measure how each residue in the µ-opioid receptor (µOR) shapes responses to 15 opioids, yielding ∼400,000 measurements of variant effects on signaling and expression, including full concentration-response series for three agonists. Mutational effects on potency are strongest near the orthosteric pocket, whereas effects on efficacy extend through the transmembrane core and intracellular face. Ligands share many functional determinants, but sensitivity to mutation differs with efficacy. As efficacy decreases, the residues required for signaling shift from the binding pocket towards the intracellular face; partial agonists therefore depend on residues that are dispensable for full agonists. Mutations can broadly increase receptor responses, allowing antagonists such as naloxone to produce signaling comparable to a full agonist and increasing the efficacy of partial agonist ligands. Combined mutations can also reorder the relative efficacies of ligands, showing that sequence changes reshape pharmacological differences rather than simply increasing or decreasing all responses together. These findings support a model in which ligands of different efficacy activate the receptor through distinct allosteric mechanisms which are determined by residues distributed across the receptor. Mapping these contributions across diverse ligands with deep mutational pharmacology provides a way to understand how one receptor converts molecular recognition into a range of signaling outputs.

Read PDF

Similar papers

Review Sep 2026

The promise of biased ligands in therapeutics.

Discovered 40 years ago but underappreciated for decades, the paradigm of biased agonism has now become standard in G protein-coupled receptor (GPCR) pharmacology and drug discovery. Biased agonism refers to the phenomenon in which different agonists binding to the same receptor result in differential activation of sig...

D. Eiger, Jeffrey S. Smith, S. Rajagopal · 0 citations
Open access Oct 2026

Ligand-dependent G protein dynamics underlying opioid efficacy

Deutsch et al. show how μ-opioid receptor agonists exert long-range allosteric control over bound G proteins, providing an additional mechanism for encoding opioid signaling outcomes.

Jonathan C. Deutsch, Daniel Hilger, John Janetzko et al. · 1 citation
Open access Sep 2026

Structural basis of endogenous inverse agonism and subtype selectivity at melanocortin receptors

Cryo-EM structures of melanocortin-1 receptor bound to its endogenous inverse agonist, agouti signaling protein (ASIP) and melanocortin-4 receptor (MC4R) bound to agouti-related protein (AgRP) are reported, establishing a mechanistic framework for endogenous inverse agonism and identifying the receptor periphery as a t...

Qin-Xin Sun, Shu-Hao Zhang, Xin Zhang et al. · 0 citations
Open access Oct 2026

Sparsely Phosphorylable Residues, Tuned by Agonist Chemotype, Shapes GPCR Signaling

It is shown that the melanocortin-4 receptor (MC4R), a central regulator of energy homeostasis, achieves remarkably diverse and pathway-selective signaling through a sparse set of strategically positioned regulatory phosphoresidues, arguing that GPCR signaling diversity does not necessarily require an extensive phospho...

M. Borah, Sarfraz Ahmed, Mahek Agrawal et al. · 0 citations
Open access Sep 2026

Allosteric pathways govern Gα protein coupling selectivity at promiscuous GPCRs

It is suggested that Gα protein selectivity is an allosterically encoded property of GPCRs and provide a conceptual framework for designing ligands and receptors with tailored Gα protein-biased signaling.

Tegvir S. Boora, Han-Yu Chen, Aaron Cho et al. · 0 citations
Open access Oct 2026

Efficacy profiling of structurally diverse cannabinoid receptor ligands across transducer-coupling assays

The full efficacy range of ligands at CB1 and CB2 (i.e., inverse agonists, neutral agonists, partial agonists, full agonists, and high-efficacy agonists) has been reported collectively across numerous laboratories and assay platforms. Canonical Gi/o and β-arrestin signaling have each been suggested to shape physiologic...

Soo Jung Oh, Christopher Lucaj, Kiera Truong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.